Group of Translational ResearchDivision of Translational Genomics (Kashiwa)
The Division of Translational Genomics closely collaborates with intramural and extramural basic and clinical researchers to develop novel anti-cancer therapeutics as well as to prove their concepts. Our division has been developing genome biomarker diagnostics, exploring rational molecular targets for anti-cancer therapies, and elucidating molecular mechanisms of oncogenesis, tumor progression, and therapeutic responses. Our division is managing a data center called SCRUM-Japan, a nation-wide cancer genome screening project for developing new anti-cancer drugs.
Katsuya Tsuchihara, MD, PhD
Hideki Makinoshima, PhD
Sachiyo Mimaki, PhD, Ayako Suzuki, PhD
The Team and What We Do
Weekly conferences for the whole division and individual research groups are held. As a SCRUM-Japan steering committee member, our division contributed to quarterly held committee meetings and ad hoc database working group meetings.
- Identification of driver gene alterations of pulmonary large-cell neuroendocrine carcinoma has been done. As well as small cell lung cancer genomes that our division published, activating mutations of PI3K pathway molecules were detected.
- Whole exome analysis of occupational cholangiocarcinoma cases has been done. These cases, exposed to high-dose halokanes, showed hypermutation and unique mutational signatures.
- The first selective fluorescent probe for class 3 ALDH (ALDH3A1) was developed. The probe will be useful for elucidating carcinogenesis of esophageal cancer.
- SCRUM-Japan data center has been integrating clinical and genome analysis data of more than 7,500 cases and distributing these data to the researchers with the collaboration of academic institutes and pharmaceutical companies.
- Screening project for Individualized Medicine in Japan (SCRUM-Japan): Data center
Academia / Training or Academia / Nuturing the Future
Our division accepted and trained the following trainees: Graduate students from the University of Tokyo and Keio University, staff physicians and residents of the National Cancer Center Hospital East, Tottori University and Keio University, visiting scientists from the Tokyo University of Science, the University of Tokyo, Tottori University, Keio University, diagnostics and IT companies.
SCRUM-Japan is establishing its reputation for a role model of cancer precision medicine. Our division will feed back the know-how to propel the clinical application of genome-based cancer precision medicine.